How government health bodies are able to move at this pace and get away with it amazes me. They continue, along w/FDA and others, to move at a pace that would get any private sector staff fired. A year to outline a basic program that could have been done in a week by any competent staff. Now wait till they are ready to start actually treat someone. Must be nice to have jobs like those and still get paid a lot of money. Some one should point out that this AD thing is a HC crisis.
If Anavex A2-73 is to be included in the NIH/ACTC it will be a huge potential catalylist for AVXL stock in just a few months. I would not want to be short "trading shares" at that time. Who is the ATCH chairman? Does he believe in A2-73 or at least think it deserves to be clinically tested? Is this why no N American sites are listed in the latest clinical trial of A2-73? I suggest Investors should connect the dots.